Silver Book Fact

Disease specific status and generic health status improvements from TAVR and SAVR

Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to 22 point improvement on a 100 point scale) and in generic health status (3.9 to 5.1 point improvement on a 36 point scale).

Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Risk: Results from PARTNER 2 Randomized Clinical Trial. JAMA Cardiology. 2017; 2(8): 837-45. https://jamanetwork.com/journals/jamacardiology/article-abstract/2635358

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Satisfaction with HVD Treatment
    Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • TAVR Procedures 2011 – 2015
    From approval in 2011 through 2015, >54,000 transcatheter aortic valve replacements (TAVRs) were performed in 418 centers in 48 states.  
  • Survival rates of SAS patients ages 80+ with and without SAVR